The first FDA-approved oral,
once-daily treatment in adults for previously treated chronic graft versus host disease (cGVHD)1,2

In a Phase 2, open-label multicenter, single arm study1 in adult patients with previously treated cGVHD (N=42),

2 out of 3 (67%) achieved a PR (45%) or CR (21%)1

  • Responses were assessed by investigators using the 2005 NIH Consensus Panel Response Criteria with two modifications to align with the updated 2014 NIH Consensus Panel Response Criteria

48% of patients had a sustained response of at least 20 weeks

  • Sustained response rate is defined as the proportion of patients who achieved a CR or PR that was sustained for at least 20 weeks

By Your Side patient support program*

Starting treatment with IMBRUVICA® can feel like a big step for patients. That’s why the By Your Side patient support program offers the information and resources your patients may need during treatment.



IMBRUVICA® (ibrutinib) is a once-daily oral therapy indicated for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. 

*IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have.

cGVHD=chronic graft versus host disease, CR=complete response, NIH=National Institutes of Health, PR=partial response.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2US Food and Drug Administration. FDA approves treatment for chronic graft versus host disease. Published August 2, 2017. Accessed May 23, 2019.